The new levonorgestrel intrauterine system, a different approach in the management of menorrhagia

Surtea L, Gherghisan O, Surtea PL
Hospital Madonna Maria, Craiova, Romania

Objective
The objective of the study was to estimate the impact of a new Levonorgestrel intrauterine system on menorrhagia.

Methods
It was a retrospective study from April 2013 to April 2015 in the Hospital Madonna Maria from Craiova, Romania to estimate the clinical usefulness of Jaydess, a contraceptive device licensed for 3 years use, which contains 13.5 mg of levonorgestrel. This study included 14 patients with known menorrhagia for at least 3 menstrual cycles.

Results
During an observation period of 2 years, we found a great reduction in menstrual blood loss, 12 (85.71%) of women became oligomenorrheic or amenorrhoeic after 12 month. For the others 2 patients (14.28%) mean blood loss did not decrease significantly. Only one advers event was possibly related to the IUS, an asymptomatic unilateral ovarian cyst at a single user (7.1%). No expulsion was reported during this study period.

Conclusion
The efficacy profiles of the new Levonorgestrel intrauterine system on menorrhagia is similar to Mirena. Jeydess is an effective and safe treatment for menorrhagia.